RESI on MaRS Innovation Challenge – Check Out the Winners

12 Apr

By Chris Cummings, Senior Marketing Manager, LSN

On April 10, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Place: Neurescence

Neurescence has developed and commercialized a miniature microscope initially targeted to the neurology research market. Our Quartet™ system gets implanted in multiple regions of the brain and spine and follows the activities of 100s of neurons in each region for months while the subject freely moves around. Our hardware-software suite is the only technology that allows establishing a causal connection between the effect of the treatment, such as a drug, on both the neuronal micro-circuitry and the disease phenotype. This extremely powerful approach takes the process of discovering and developing treatments from a trial and error method to an intelligent design.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Yasaman Soudagar, Founder & CEO, Neurescence | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

Second Prize: Acorn Biolabs

People’s own cells have and will continue to become the foundation of the most important future biomedical therapeutics and regenerative medicine strategies. Aged cells, however, are highly mutated and deteriorated versions of our current cells. Precisely when people will need high-quality cells the most, their cells at that time will be at their worst. Acorn Biolabs has developed a novel non-invasive at-home kit to collect and viably transport cells. Acorn cryopreserves these cells as a way to ensure people will always have access to their own young therapeutically-capable cells. The value potential is immense; customer’s preserved cells are a life-long living resource, retrievable for direct use with advanced cell-based therapeutics, and analyzable for personal genomics, epigenomics, proteomics and beyond.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Steven ten Holder, Founder & COO, Acorn Biolabs | Drew Taylor, CEO, Acorn Biolabs | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

Third Prize: Therachat

Therachat is a mental health platform which simplifies homework in therapy for therapists & psychologists & their clients. Therapists & psychologists can customize the homework experience for their clients via a simple web application and their clients can do their homework on an easy-to-use, HIPAA compliant, mobile application. We believe that homework needed a simpler way and that’s what we have built! Check http://www.therachat.io to find out more!

Sajid Reshamwala, Director of Design, Therachat | Kouris Kalligas, CEO & Founder, Therachat | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

If you missed out on the opportunity to compete in the RESI on MaRS Innovation Challenge, we’d be happy to take your application for our upcoming Boston event on June 4th.

Apply for RESI Boston Innovation Challenge Now!

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: